Curia Global Inc.

Albany, NY Doing business as Amri

UEI
ELCNZCS8GEA3
CAGE
3D1R9
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Show all
Corporate family
SAM.gov registration date
Physical address
21 Corporate Cir, Albany, NY 12203, USA
Website
curiaglobal.com
Founded
1991
Employees
1K-5K
Estimated annual revenue
$250M-$500M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Curia Global Inc.

Curia Global Inc., doing business as Amri, is a leading global contract development and manufacturing organization (CDMO) specializing in pharmaceutical research and development services. Registered in SAM.gov since 2003, the company is a for-profit organization and manufacturer of goods that provides comprehensive support to federal agencies, particularly within the National Institutes of Health (NIH) ecosystem. The company offers end-to-end pharmaceutical development services ranging from early-stage drug discovery through commercialization, with a strong focus on therapeutic areas including neurology, infectious diseases, substance abuse, and translational sciences.

Through its federal contract awards, Curia Global Inc. has consistently demonstrated expertise in highly specialized pharmaceutical research and development services. The company has secured numerous delivery orders and purchase orders from agencies like the National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Allergy and Infectious Diseases (NIAID), National Center for Advancing Translational Sciences (NCATS), and National Institute on Drug Abuse (NIDA). These contracts typically involve complex scientific work such as medicinal chemistry, hit-to-lead chemistry, chemical development, analytical testing, absorption/distribution/metabolism/excretion (ADME) testing, process chemistry, scale-up synthesis, good manufacturing practices (GMP) production, stability testing, and nonclinical services. The contracts span various therapeutic research initiatives, including drug discovery for conditions like Alzheimer's, Parkinson's, pain management, stroke, and infectious diseases. Notably, none of the contract awards have had specific small business set-aside designations, indicating Curia Global Inc. competes effectively as a large business contractor.

Regarding federal grant awards, Curia Global Inc. has at least one significant cooperative agreement with the Joint PEO Chemical and Biological Defense, focused on COVID-19 action efforts. Specifically, the grant award W58P052220004 aims to expand and accelerate domestic manufacturing related to medical, chemical, and biological countermeasures, with a particular emphasis on fill/finish production. The grant has a substantial period of performance, running from March 2022 to March 2035, suggesting a long-term commitment to supporting national biodefense and pandemic response capabilities. Additionally, the company has engaged in sub-contract work with prime contractors like The Leland Stanford Junior University, performing specialized chemical process development, manufacturing, and analytical activities for specific drug substance research programs. These sub-contract activities demonstrate Curia Global Inc.'s flexibility and technical expertise in supporting complex scientific research initiatives across different organizational partnerships.

Contract vehicles

Quick answers

What is Curia Global Inc.'s UEI?

Curia Global Inc.'s Unique Entity ID (UEI) in SAM.gov is ELCNZCS8GEA3.

What is Curia Global Inc.'s CAGE code?

Curia Global Inc.'s CAGE code is 3D1R9.

What is Curia Global Inc.'s primary NAICS code?

Curia Global Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).

Where is Curia Global Inc. located?

Curia Global Inc.'s physical address in SAM.gov is 21 Corporate Cir, Albany, NY 12203, USA.

Is Curia Global Inc. registered in SAM.gov?

Yes. Curia Global Inc.'s SAM.gov registration is active through May 18, 2027.

Which contract vehicles does Curia Global Inc. hold?

Curia Global Inc. holds a place on 3 federal contract vehicles, including CRO Support for NCATS Drug Substance Development and Manufacture, DMFP and Nonclinical Services for Development of Interventional Agents.

What is Curia Global Inc.'s most recent federal award?

Curia Global Inc.'s most recent federal contract award is Exploratory chemistry and HIT-to-lead chemistry option. Medicinal chemistry support program for therapeutic… (75N98026F00001), from Office of Logisitics and Acquisition Operations, on September 21, 2026.

On GovTribe

See Curia Global Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors